医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Terns Pharmaceuticals Announces the Addition of Juan Carlos Lopez-Talavera, M.D., Ph.D. and Chuan Shih, Ph.D., as Scientific Advisors

2018年04月13日 PM09:00
このエントリーをはてなブックマークに追加


 

SAN MATEO, Calif. & SHANGHAI

Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver disease and cancer, announced today the addition of Juan Carlos Lopez-Talavera, M.D., Ph.D. and Chuan (Joe) Shih, Ph.D. as scientific advisors.

“As we prepare to enter the clinic with two lead compounds, TERN-101 and TERN-201 for the treatment of non-alcoholic steatohepatitis (NASH) in multiple markets, having Dr. Lopez-Talavera and Dr. Shih as resources will be invaluable,” said Weidong Zhong, Ph.D., President and CEO of Terns. “Their expertise in liver disease and oncology drug discovery and development is highly relevant and complimentary to that of our internal team and we have already started integrating them into their advisory function.”

Juan Carlos Lopez-Talavera, M.D., Ph.D.
Dr. Lopez-Talavera has over 20 years of experience in the biopharma industry, with extensive expertise in liver and gastrointestinal diseases. Most recently, Dr. Lopez-Talavera was Senior Vice President, Head of Medical Affairs and member of the Executive Team at Intercept Pharmaceuticals. Previously he held positions at AbbVie as Head of Medical Affairs, Global Research and Development, Bristol Myers Squibb, where he was Vice President and Global Development Lead, and at Roche Laboratories as Senior Medical Director. Before moving into industry, Dr. Lopez-Talavera was Assistant Professor with the Divisions of Gastroenterology and Hepatology, and Endocrinology and Pathology at the University of Pittsburgh Medical Center and Associate Professor of Medicine with the Universidad Autónoma de Barcelona and Attending Physician of the Liver Unit at the Hospital General Universitari Vall D’Hebron in Barcelona.

Dr. Lopez-Talavera was a Postdoctoral Fellow at the Yale University School of Medicine, and Clinical Observer at Sloan Kettering Memorial Cancer Center. He holds an M.D. and a Ph.D. in Hepatology from the Universidad Autónoma de Barcelona.

Chuan (Joe) Shih, Ph.D.
Dr. Shih is currently a Venture Partner of Lilly Asia Ventures with over 30 years of experience working within the life sciences industry. Before joining Lilly Asia Ventures, he was the Director of the Institute of Biotechnology and Pharmaceutical Research (IBPR) of the National Health Research Institutes (NHRI), a premier new drug discovery institute in Taiwan. Prior to IBPR, Dr. Shih led drug discovery and translational medicine teams across multiple therapeutic areas at Crown Biosciences, Inc., Lilly Research Laboratories and Eli Lilly and Company. Over his career, Dr. Shih has led discovery efforts that have resulted in or contributed to multiple successful commercial products. He received numerous achievement awards throughout his career including the 2006 American Chemical Society “Heroes of Chemistry” Award for his role in the discovery and development of Alimta®.

Dr. Shih received his Ph.D. in organic chemistry from Ohio State University. He completed a postdoctoral fellowship at Harvard University under Nobel Laureate Professor E. J. Corey.

About Terns Pharmaceuticals

Based in San Mateo, CA., and Shanghai, China, Terns Pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly targeted, oral, small molecule drugs to treat liver disease and cancer. The company combines expertise in disease biology, medicinal chemistry and extensive clinical development capabilities in China to advance its growing pipeline of drugs that are optimized against clinically validated targets or targets that have significant preclinical validation. Using a capital-efficient drug discovery model, the company’s mission is to bring promising new therapies to patients in underserved markets via global and region-specific development programs. For more information, visit www.TernsPharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180413005139/en/

CONTACT

Terns Pharmaceuticals Inc.
US Media Contact:
Cory
Tromblee, 617-571-7220
or
China Media Contact:
Eddy
Wu, + 86 180 1631 1449

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ポットネットワーク・ホールディングス傘下のダイヤモンドCBDが全米のショッピングモールで製品を販売する計画を発表
  • Gynesonics Technology to Be Featured in Presentations at 2018 American Association of Gynecologic Laparoscopists Global Congress
  • Takeda Announces Publication of Circular and Notice of Extraordinary General Meeting of Shareholders in Relation to the Proposed Acquisition of Shire
  • 武田薬品が第60回米国血液学会年次総会で血液がんの広範な治療ニーズに関するデータを発表へ
  • 武田将在美国血液学会第60届年会上呈报各类血液肿瘤治疗需求数据